Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers: Letter to the editor

APMIS

Volumn 118, Issue 1, 2010, Pages 83-84

  Park, Sang Wook ^a   Chung, Nak Gyun ^a   Han, Ji Youn ^b   Eom, Hyeon Seok ^c   Yoo, Nam Jin ^a   Lee, Sug Hyung ^a  

^a The Catholic University of Korea   (South Korea)

^b National Cancer Center   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; GENOMIC DNA; TRASTUZUMAB;

AUTORADIOGRAPHY; BREAST CANCER; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL GROWTH; CELL SURVIVAL; CELL TRANSFORMATION; DNA EXTRACTION; DNA SEQUENCE; EXON; GENE ACTIVATION; GENE AMPLIFICATION; GENE DELETION; GENE TARGETING; HUMAN; LETTER; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 73149115292     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02565.x     Document Type: Letter

References (8)

1. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003 284 : 31 53.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 : 1497 500.
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999 17 : 2639 48.
4. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006 12 : 57 61.
5. Soung YH, Lee JW, Kim SY, Wang YP, Jo KH, Moon SW, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006 118 : 1426 9.
6. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, et al. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 2009 34 : 641 51.
7. Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, et al. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 2007 97 : 1560 6.
8. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005 11 : 3750 7.